Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis
Medicine: Case Reports and Study Protocols · 2021
DOI: 10.1097/md9.0000000000000029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine: Case Reports and Study Protocols, 2021. Verfasst von Shintaro Yamamoto und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rationale
Certolizumab pegol (CZP) is a tumor necrosis factor (TNF) inhibitor with the unique characteristic of being a humanized Fab′ fragment. Immunoglobulin A (IgA) vasculitis has been reported to be associated with the use of TNF inhibitors, including infliximab, etanercept, and adalimumab. Patient concerns: The case was a 34-year-old Japanese woman with rheumatoid arthritis who had been treated with CZP for 3 years. She had delivered a healthy child 5 months earlier. On presentation, she had a 2-day history of abdominal pain and purpura on the lower extremities. Diagnoses: Histological analyses of a skin specimen revealed inflammatory cell infiltrates around the vessel walls and IgA and C3 deposits in the vessel walls of the upper dermis. Computed tomography showed terminal ileitis. The diagnosis was IgA vasculitis, presumably associated with use of CZP.
Intervention
CZP was discontinued and prednisolone was administered. Outcomes: The abdominal pain and purpura promptly improved in response to treatment. No relapse of vasculitis occurred after discontinuation of CZP. Lessons: In this case, the cumulative immunomodulatory effects of the TNF inhibitor and the patient postpartum status were considered to be involved in inducing IgA vasculitis. Clinicians should be aware of IgA vasculitis-related symptoms as a possible adverse effect of TNF inhibitors to ensure prompt diagnosis and appropriate treatment.
Zitieren
APA
Yamamoto, S., Mukai, T., Fujita, S., & Morita, Y. (2021). Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis. Medicine: Case Reports and Study Protocols. https://doi.org/10.1097/md9.0000000000000029
Vancouver
Yamamoto S, Mukai T, Fujita S, Morita Y. Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis. Medicine: Case Reports and Study Protocols. 2021. doi:10.1097/md9.0000000000000029
BibTeX
@article{Yamamoto2021,
author = {Yamamoto, Shintaro and Mukai, Tomoyuki and Fujita, Shunichi and Morita, Yoshitaka},
title = {Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis},
journal = {Medicine: Case Reports and Study Protocols},
year = {2021},
doi = {10.1097/md9.0000000000000029}
}
EUVIMED